Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions

Covid19Corona Virus InfectionSARS-CoV InfectionARDSCoronavirus

Interventions

BIOLOGICAL

Umbilical Cord Lining Stem Cells (ULSC)

IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection

OTHER

Placebo (carrier control)

IV infusion of carrier control consisting of sterile saline for injection

Trial Locations (2)

Miami Baptist Hospital, Miami

Sanford Research, Sioux Falls

All Listed Sponsors

lead

Restem, LLC.

INDUSTRY

NCT04494386 - Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS | Biotech Hunter | Biotech Hunter